4//SEC Filing
Niklason Laura E 4
Accession 0001818382-24-000208
CIK 0001818382other
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 7:06 PM ET
Size
11.8 KB
Accession
0001818382-24-000208
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Niklason Laura E
DirectorPresident, CEO and Director
Transactions
- Sale
Common Stock
2024-11-20$4.40/sh−261,369$1,150,024→ 1,730,884 total(indirect: By LLC) - Sale
Common Stock
2024-11-18$4.44/sh−811,172$3,601,604→ 2,419,712 total(indirect: By LLC) - Sale
Common Stock
2024-11-19$4.34/sh−427,459$1,855,172→ 1,992,253 total(indirect: By LLC)
Holdings
- 242,054
Common Stock
- 1,148,240(indirect: By Trust)
Common Stock
- 510,161(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
- [F2]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001878075
Filing Metadata
- Form type
- 4
- Filed
- Nov 19, 7:00 PM ET
- Accepted
- Nov 20, 7:06 PM ET
- Size
- 11.8 KB